Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Am J Kidney Dis. 2013 Jun;61(6):966-74. doi: 10.1053/j.ajkd.2012.12.023. Epub 2013 Mar 6.
Blood pressure is known to fluctuate widely during hemodialysis; however, little is known about the association between intradialytic blood pressure variability and outcomes.
Retrospective observational cohort.
SETTING & PARTICIPANTS: A random sample of 6,393 adult, thrice-weekly, in-center, maintenance hemodialysis patients dialyzing at 1,026 dialysis units within a single large dialysis organization.
Intradialytic systolic blood pressure (SBP) variability. This was calculated using a mixed linear effects model. Peridialytic SBP phenomena were defined as starting SBP (regression intercept), systematic change in SBP over the course of dialysis (2 regression slopes), and random intradialytic SBP variability (absolute regression residual).
All-cause and cardiovascular mortality.
SBPs (n = 631,922) measured during hemodialysis treatments (n = 78,961) during the first 30 days in the study. Outcome data were obtained from the dialysis unit electronic medical record and were considered beginning on day 31.
High (ie, greater than the median) versus low SBP variability was associated with greater risk of all-cause mortality (adjusted HR, 1.26; 95% CI, 1.08-1.47). The association between high SBP variability and cardiovascular mortality was even more potent (adjusted HR, 1.32; 95% CI, 1.01-1.72). A dose-response trend was observed across quartiles of SBP variability for both all-cause (P = 0.001) and cardiovascular (P = 0.04) mortality.
Inclusion of patients from a single large dialysis organization, over-representation of African Americans and patients with diabetes and heart failure, and lack of standardized SBP measurements.
Greater intradialytic SBP variability is associated independently with increased all-cause and cardiovascular mortality. Further prospective studies are needed to confirm findings and identify means of reducing SBP variability to facilitate randomized study.
血压在血液透析过程中波动很大;然而,关于透析期间血压变异性与结局之间的关系知之甚少。
回顾性观察性队列研究。
从一个单一的大型透析机构内的 1026 个透析单位中随机抽取了 6393 名成年、每周三次、中心维持性血液透析患者作为一个随机样本。
透析期间收缩压(SBP)变异性。这是使用混合线性效应模型计算的。透析期间 SBP 现象定义为起始 SBP(回归截距)、透析过程中 SBP 的系统变化(2 个回归斜率)和随机透析期间 SBP 变异性(绝对回归残差)。
全因和心血管死亡率。
在研究的前 30 天内,血液透析治疗期间(n = 631922)测量了 SBP(n = 78961)。通过透析单位电子病历获得结局数据,自第 31 天开始考虑。
与低 SBP 变异性相比,高(即大于中位数)SBP 变异性与全因死亡率风险增加相关(调整后的 HR,1.26;95%CI,1.08-1.47)。高 SBP 变异性与心血管死亡率之间的关联更为强烈(调整后的 HR,1.32;95%CI,1.01-1.72)。对于全因(P = 0.001)和心血管(P = 0.04)死亡率,SBP 变异性的四分位区间均观察到剂量反应趋势。
纳入来自单个大型透析机构的患者,非洲裔美国人、糖尿病和心力衰竭患者的比例过高,以及缺乏标准化的 SBP 测量。
透析期间更大的 SBP 变异性与全因和心血管死亡率的增加独立相关。需要进一步的前瞻性研究来证实这些发现,并确定降低 SBP 变异性的方法,以促进随机研究。